LeoGordonMD

Hematology • Chicago, IL

Hematologic Oncology

Robert H. Lurie Comprehensive Cancer Center

Join to view full profile

Dr. Gordon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gordon's full profile

Already have an account?

Office
675 N Saint Clair St
# Galter
Chicago, IL 60611
Phone+1 312-695-0990

Fax+1 312-695-6189

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1979
University of MinnesotaFellowship, Hematology and Medical Oncology, 1978
University of ChicagoResidency, Internal Medicine, 1973 - 1976
University of ChicagoInternship, Internal Medicine, 1973 - 1974
University of Cincinnati College of MedicineClass of 1973

Certifications & Licensure

IL State Medical License 1974 - 2026
MN State Medical License 1976 - 1978
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Fellow (FACP) American College of Physicians, 2007
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL Start of enrollment: 2003 Oct 28
Terminated
Phase 1, Phase 2
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma Start of enrollment: 2006 Apr 07
Terminated
Phase 1, Phase 2
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma Start of enrollment: 2007 Feb 06
Completed
Phase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma Start of enrollment: 2011 Nov 01
Active, not recruiting
Phase 2
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Start of enrollment: 2013 Mar 05
Terminated
Phase 1, Phase 2
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Start of enrollment: 2016 Jan 06
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

79 citations
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transpla...
Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani
The Lancet. Oncology. 2022-08-01
545 citations
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Frederick L Locke, David B Miklos, Caron A Jacobson, Miguel-Angel Perales, Marie-José Kersten
The New England Journal of Medicine. 2022-02-17
21 citations
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
Joanna Zurko, Imran Nizamuddin, Narendranath Epperla, Kevin David, Jonathon B Cohen
Blood Advances. 2023-06-27

Abstracts/Posters

Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Mul...
Leo I. Gordon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects in an Immune Competent Lymphoma Model
Leo I. Gordon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
Leo I. Gordon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classi...
Leo I. Gordon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Bio-Inspired Functional Lipoprotein-like Nanoparticles (Flip-NPs) Cause Cholesterol Starvation and Ferroptosis in B-Cell Lymphomas: Studies in Cell Lines, Xenograft Mo...
Leo I. Gordon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
Leo I. Gordon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
Leo I. Gordon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Inhibition of Pro-Survival Pathways in DLBCL Cells By Functional Lipoprotein-like Nanoparticles
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Studyof Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monot...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

$Data from Phase 2 PILOT Study of Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy$
Data from Phase 2 PILOT Study of Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line TherapyMay 27th, 2022
New Alternative for Relapsed B-cell LymphomaJanuary 26th, 2022
Expert Discusses JCAR017 CAR T-cell Therapy in Non-Hodgkin LymphomaMarch 6th, 2017
Join now to see all